Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista (sotagliflozin)

Shots:

• Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista for T1D & T2D and coordinate with Sanofi in the transition of ongoing clinical studies and other activities
• In Jul’2019, Sanofi has terminated its 4yrs. partnership following the disappointing results of three P-III studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients
• Zynquista is an oral dual inhibitor of SGLT1 and SGLT2, approved as an adjunct to insulin therapy to improve glycemic control in T1D patients in Europe. Lexicon is planning to file regulatory approval in the US & EU for T2D with the expected ongoing P-III study results demonstrating CV & renal benefits

Click here to­ read full press release/ article | Ref: lexicon| Image: Chicago Tribune